ReviewMicroorganisms2021
Diabetes-Associated Susceptibility to Tuberculosis: Contribution of Hyperglycemia vs. Dyslipidemia.
Review in Microorganisms, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 39 citations in OpenAlex.
- Lipid profile alterations in pulmonary tuberculosis patients with and without diabetes mellitus: a systematic review and meta-analysis.BMC infectious diseases · 2026Pooled it
- The Impact of Optimal Glycemic Control on Tuberculosis Treatment Outcomes in Patients With Diabetes Mellitus: Systematic Review and Meta-Analysis.JMIR public health and surveillance · 2024Pooled it
- A QuantiFERONInfection and drug resistance · 2026Article
- Article
- Global burden of 13 non-communicable diseases attributable to high fasting plasma glucose from the GBD 2021 study.Nutrition & diabetes · 2025Article
- Factors associated with treatment outcomes (cured, completed, defaulted, and death) among TB/HIV co-infected patients in East Coast Malaysia: A 5-year record review (2016-2020).BMC infectious diseases · 2025Article
- Diet-induced dyslipidemia enhances IFN-γ production in mycolic acid-specific T cells and affects mycobacterial control.Mucosal immunology · 2025Article
- Diabetes and tuberculosis: a systematic review and meta-analyis of mendelian randomization evidence.Diabetology & metabolic syndrome · 2025Review
- The gut and lung microbiome across the TB disease spectrum.Frontiers in microbiology · 2025Review
- Assessment of comorbidities, risk factors, and post tuberculosis lung disease in National Tuberculosis Guidelines: A scoping review.PLOS global public health · 2025Article
- Enhanced Rapid Screening for Multidrug-resistant tuberculosis through combined cardiometabolic and inflammatory indices: a cross-sectional study.Scientific reports · 2024Article
- The Association between Dyslipidemia and Pulmonary Diseases.Journal of atherosclerosis and thrombosis · 2024Review
- T Cell Responses during Human Immunodeficiency Virus/Vaccines · 2024Review
- Characterising the urinary acylcarnitine and amino acid profiles of HIV/TB co-infection, using LC-MS metabolomics.Metabolomics : Official journal of the Metabolomic Society · 2024Article
- Metabolic changes enhance necroptosis of type 2 diabetes mellitus mice infected with Mycobacterium tuberculosis.PLoS pathogens · 2024Article
- Article
- Increasing HbA1c is associated with reduced CD8Cellular and molecular life sciences : CMLS · 2024Article
- Effect of hyperglycemia on lung microbiota and treatment outcome in pulmonary tuberculosis: A scoping review.F1000Research · 2024Article
- Role of Clinical Features, Pathogenic and Etiological Characteristics of Community-acquired Pneumonia with Type 2 Diabetes Mellitus in Early Diagnosis.Endocrine, metabolic & immune disorders drug targets · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Diabetes is a major risk factor for tuberculosis (TB). Diabetes increases the risk of the progression from latent tuberculosis infection (LTBI) to active pulmonary TB and TB patients with diabetes are at greater risk of more severe disease and adverse TB treatment outcomes compared to TB patients without co-morbidities. Diabetes is a complex disease, characterised not only by hyperglycemia but also by various forms of dyslipidemia. However, the relative contribution of these underlying metabolic factors to increased susceptibility to TB are poorly understood. This review summarises our current knowledge on the epidemiology and clinical manifestation of TB and diabetes comorbidity. We subsequently dissect the relative contributions of body mass index, hyperglycemia, elevated cholesterol and triglycerides on TB disease severity and treatment outcomes. Lastly, we discuss the impact of selected glucose and cholesterol-lowering treatments frequently used in the management of diabetes on TB treatment outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.